Tofacitinib helped a woman with total-body hair loss grow her hair back.
16 citations,
January 2022 in “International journal of molecular sciences” Certain daily habits like stress, diet, and sleep can affect the severity of hair loss in alopecia areata.
15 citations,
February 2020 in “Experimental Dermatology” The document concludes that understanding and treatments for alopecia areata have significantly advanced, now recognizing it as an autoimmune disorder.
6 citations,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
2 citations,
January 2023 in “Pharmaceuticals” Natural products and phytochemicals may help with hair regrowth, but more research is needed.
1 citations,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” New treatments and strategies are needed for Alopecia Areata, focusing on immune response and better trial designs.
August 2024 in “Current Protocols” The C3H/HeJ mouse model is useful for studying and testing treatments for alopecia areata.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
6 citations,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
7 citations,
June 2019 in “Cureus” Fractional lasers and microneedling, combined with topical agents, could potentially treat Alopecia Areata effectively, but more research is needed due to limited data.
4 citations,
January 2020 in “Lasers in Surgery and Medicine” Using a 308-nm excimer lamp with minoxidil promotes hair growth in Alopecia Areata patients, especially younger ones or those with smaller bald spots.
2 citations,
November 2020 in “Der Hautarzt” A patient's hair loss may be linked to their diabetes medication, Sitagliptin.
144 citations,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
13 citations,
February 2016 in “Clinical Medicine” The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.
9 citations,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
2 citations,
January 2017 in “Clinical and medical investigations” Herbal lotions are effective for severe hair loss, with a 64.8% success rate, but relapse is common and long-term management requires allergen control and possible corticosteroid use.
1 citations,
July 2014 in “International Journal of Dermatology” A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
January 2023 in “Rossijskij žurnal kožnyh i veneričeskih boleznej” New treatments for child hair loss due to immune issues are effective but not yet officially approved.
February 2021 in “Journal of pharmaceutical and biological sciences” No cure exists for alopecia areata, and treatments are personalized.
January 2015 in “British journal of medicine and medical research” A woman with severe hair loss due to systemic sclerosis regrew her hair in 4 months using a combination of treatments.
January 2015 in “Przegla̧d dermatologiczny” Intralesional triamcinolone is the most effective treatment for alopecia areata, followed by excimer light therapy, and then topical minoxidil. The scalp responds better to treatment than the beard area.
8 citations,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
40 citations,
February 2012 in “Dermatology Online Journal” Lasers might help hair growth in some alopecia cases, but more research is needed to confirm their effectiveness and safety.
2 citations,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
6 citations,
September 2015 in “Journal of theoretical biology” The model showed that immune system guardians and the cytokine interferon-γ are key in alopecia areata progression.
52 citations,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
11 citations,
December 2018 in “Journal of the European Academy of Dermatology and Venereology” Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.